| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6183 |
Project Team
| Project lead | Emily Richards |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 July 2023 | In progress. Scoping commenced. Please note that the evaluation of selpercatinib for untreated RET-positive advanced thyroid cancer ID6183, will now be conducted via ID6132 selpercatinib for untreated advanced thyroid cancer with RET alterations. |
| 25 October 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual